
Femmeola 150mg Tablet
Salt Composition: Olaparib
Expiry Date: 01/2028
Inclusive of all taxes
120 Tablets in Bottle
About The Product
Ovarian Cancer, Breast Cancer
Description
Femmeola 150mg Tablet is an anticancer medication prescribed by the doctor to treat ovarian, breast, pancreatic, and prostate cancers, particularly in patients with certain genetic mutations like BRCA.
Femmeola 150mg Tablet contains olaparib that inhibits cancer cell growth and proliferation.
Uses
- Ovarian, Breast, Pancreatic, and Prostate Cancers with Genetic Mutations
Side Effects
Femmeola 150mg Tablet is a target therapy based medication. Immediately consult to your doctor, if side effects persist for a longer length of time.
- Constipation
- Reduced Appetite
- Headache
- Vomiting
- Sweating
- Fatigue
- Taste Change
- Body Ache
- High Blood Pressure
- Mouth Sore
- Risk of Infection
- Blood Clots
- Heart Problems
- Neurological Issues
How To Use
- Femmeola 150mg Tablet containing is taken orally. Tablet is swallowed as it is with the help of water. It can be taken after or before food consumption.
- Avoid crushing, chewing, breaking or biting of tablet to maintain its efficacy. For more personalized assistance and exact dosage, talk to your doctor about the same.
How It Works
- Femmeola 150mg Tablet (olaparib) prevents cancer cells by repairing single-strand DNA breaks by inhibiting PARP enzymes, mainly PARP1 and PARP2.
- PARP suppression locks the enzyme on DNA in cancers with BRCA1/2 or other homologous recombination repair (HRR) abnormalities, triggering replication fork collapse into double-strand breaks that overburdened cells are unable to repair, resulting in synthetic lethality and apoptosis.
Safety Advice
FAQs
The purpose of Femmeola 150mg Tablet is to treat ovarian, breast, pancreatic, and prostate cancers, particularly in patients with certain genetic mutations like BRCA.
References
- Bochum, S., Berger, S., & Martens, U. M. (2018). Olaparib. Small molecules in oncology, 217-233.
- Gou, R., Horikawa, N., & Kosaka, K. (2022). Olaparib-induced cutaneous side effects in a patient with recurrent ovarian cancer. BMJ Case Reports CP, 15(4), e249177. https://pubmed.ncbi.nlm.nih.gov/35444023/
- Zhou, Y., Zhao, S., Wu, T., & Zhang, H. (2022). Comparison of adverse reactions caused by olaparib for different indications. Frontiers in pharmacology, 13, 968163. https://pmc.ncbi.nlm.nih.gov/articles/PMC9326361/
- Che, H., Wang, L. W., Ye, X. Y., & He, X. (2025). Olaparib research update: Mechanism, structure and clinical trials. Medicinal Chemistry Research, 34(3), 535-548.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.jpeg%3FupdatedAt%3D1763121181831&w=128&q=75)
